LectureLinx

Security and trust center evidence

Scalable Technology and Expertise for Pharma and Life Science

lecturelinx.com Life sciences and biotechLast verified 17 Sep 2026

LectureLinx has , and 1 expired in the CertReports index, last verified 17 Sep 2026. The strongest row is EU-US Data Privacy Framework: Inactive. This page is independent of the vendor’s own trust centre: dates, sources and caveats come from CertReports captures.

Reviewer brief

As of 17 Sep 2026, CertReports holds 1 expired row for LectureLinx, drawn from the Data Privacy Framework list. LectureLinx previously appeared with EU-US Data Privacy Framework evidence, but the listing is no longer active and CertReports found no renewal as of 17 Sep 2026. No public evidence was found for SOC 2, ISO/IEC 27001, HIPAA and GDPR as of 17 Sep 2026; that is a gap in the public record, not a finding of non-coverage, and the vendor can supply it under NDA.

EU-US Data Privacy Framework: Inactive, expired as of 17 Sep 2026

Facts only, each dated; nothing here is inferred, scored or advised.

Among life sciences and biotech vendors

0verified rows

Category median 0, across 43 indexed life sciences and biotech vendors. LectureLinx has more verified rows than 53 percent of them.

Compare with similar vendors

Pick your own comparison

Compliance grid

EU-US Data Privacy FrameworkExpired
Inactive
as of 17 Sep 2026
1 source

No public evidence yet for HIPAA, SOC 2, GDPR, FedRAMP, PCI DSS, ISO 27001, CSA STAR, Cyber Essentials, ISO 27701, ISO 42001. This does not mean the vendor lacks them; it means nothing public was found at the last check.

Legal artefacts

No DPA, BAA or subprocessor list has been captured from a public page yet. Registry rows above do not depend on this.

Subprocessors

No subprocessor list captured yet.

Change history

18 Sep 2026First indexed by CertReports1 evidence row across 1 framework entered the index.

Similar vendors with evidence

Related by product tags and the Life sciences and biotech category, ranked by shared tags, description similarity and overlapping evidence. Never by popularity.